MedPage Today November 15, 2024
— New research focuses on interventions for highest-risk patients
Although the general population now has at least some immunity against COVID-19, the consequences of severe disease are frequently overlooked for certain patient populations, such as those with comorbidities or immune compromise. However, new research into COVID prophylaxis and therapeutics offers some hope that novel treatments may be on the horizon.
Is Paxlovid Still Useful?
The original phase II/III EPIC-HR trial showed that nirmatrelvir/ritonavir (Paxlovid) was nearly 89% effective for preventing COVID hospitalization and all-cause death in unvaccinated high-risk patients.
“These were remarkable findings, but this trial was conducted early on in the pandemic among unvaccinated high-risk patients and the applicability of these findings to current settings of high population immunity...
Today's Sponsors
Today's Sponsor